Strategic Diagnostics Announces ISO Certification

Adds to SDI`s Growing List of Quality Certifications
NEWARK, Del.--(Business Wire)--
Strategic Diagnostics Inc. (NASDAQ:SDIX), today announced that American Systems
Registrar, an ANAB Accredited International Registrar for the ISO 9001
standards, recently granted Strategic Diagnostics an ISO 9001:2000 certification
for all five of the Company`s facilities. Recognized and respected worldwide,
ISO 9001:2000 standards are put forth by the International Organization for
Standardization (ISO).

The ISO 9001:2000 standard offers a template for the development and operation
of a business management system that is dynamic and flexible, focused on
exceeding the needs of customers and suppliers alike.

"This certification demonstrates our commitment to excellence in product and
service quality, and a continued focus on improving the customer experience,"
said Francis M. DiNuzzo, President and CEO of Strategic Diagnostics Inc. "SDI
continues to expand its competencies with a strong focus on quality and
innovation. As a result we are building a leadership position in the Life
Science market with a full suite of custom immunosolutions based on our antibody
expertise and in the food safety marketplace with a growing portfolio of rapid
pathogen detection solutions. Our customers know that they can rely on SDI to
consistently meet or exceed their expectations. SDI is committed to providing
products and services of the highest quality. The Company is cGMP compliant and
holds numerous USDA certifications. SDI has facilities in Delaware, Maine, Texas
and the UK. The ISO certification reflects the conformance of the Company`s
quality and business management systems and processes, used in the design,
manufacture and packaging of its products."

About the International Organization for Standardization

The International Organization for Standardization (ISO) is the world's largest
developer and publisher of International Standards. ISO is a network of the
national standards institutes from 158 countries. Between 1947 and the present
day, ISO has published more than 17,500 International Standards, ranging from
standards for activities such as agriculture and construction, through
mechanical engineering, to medical devices, to the newest information technology
developments.

About Strategic Diagnostics Inc.

Strategic Diagnostics Inc. is a leading provider of antibody technology to the
Life Science marketplace. Additionally the company provides biotechnology-based
detection solutions for a broad range of food, water, agricultural, and
environmental applications. By applying its core competencies of antibody and
assay development, the Company produces unique, sophisticated reagents, reagent
systems, antibody design services and bio-detection solutions to customer needs.
Customers benefit from the enablement of their research into critical health
care challenges of disease understanding, therapeutic development and diagnostic
discovery. Industrial customers benefit with quantifiable "return on investment"
by reducing time, labor, and/or material costs. All this is accomplished while
increasing accuracy, reliability and actionability of essential test results.
The Company is focused on sustaining this competitive advantage by leveraging
its expertise in antibody design, immunology, proteomics, bio-luminescence and
other bio-reactive technologies to continue its successful customer-focused
research and development efforts. Recent innovations in high throughput
production of antibodies from genetic antigens will complement the Company`s
established leadership in commercial and custom antibody production for the
Research, Human/Animal Diagnostics, and Pharmaceutical industries, and position
the Company for broader participation in proteomics research and discovery.

This news release contains forward-looking statements reflecting SDI's current
expectations. When used in this press release, the words "anticipate", "could",
"enable", "estimate", "intend", "expect", "believe", "potential", "will",
"should", "project" "plan" and similar expressions as they relate to SDI are
intended to identify said forward-looking statements. Investors are cautioned
that all forward-looking statements involve risks and uncertainties, which may
cause actual results to differ from those anticipated by SDI at this time. Such
risks and uncertainties include, without limitation, changes in demand for
products, delays in product development, delays in market acceptance of new
products, retention of customers and employees, adequate supply of raw
materials, the successful integration and consolidation of the Maine production
facilities, inability to obtain or delays in obtaining fourth party, including
AOAC, or required government approvals, the ability to meet increased market
demand, competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully described in
SDI's public filings with the U.S. Securities and Exchange Commission.

Strategic Diagnostics Inc.
Hilary Bond, 302-456-6789
www.sdix.com
or
Investor Contact:
The Trout Group
Brian Korb, 646-378-2923
bkorb@troutgroup.com

Copyright Business Wire 2009